Name: CL2A-Chimmitecan
Brand: BOC Sciences
Rating: 5 (1 reviews)

Size

Price

Stock

Quantity

$--

In stock

Synonyms

CL2A-Chimmitecan dichloroacetate salt

IUPAC Name

(S)-10-allyl-4-ethyl-9-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl (4-((S)-2-(4-aminobutyl)-35-(4-((4-((2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)methyl)cyclohexane-1-carboxamido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9-diazapentatriacontanamido)benzyl) carbonate;2,2-dichloroacetic acid

Canonical SMILES

O=C(OCC1=CC=C(C=C1)NC(=O)C(NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCN2N=NC(=C2)CNC(=O)C3CCC(CN4C(=O)C=CC4=O)CC3)CCCCN)OC5(C(=O)OCC=6C(=O)N7C(=CC65)C=8N=C9C=CC(O)=C(C9=CC8C7)CC=C)CC.C(C(=O)O)(Cl)Cl

InChI

InChI=1S/C74H97N11O22.C2H2Cl2O2/c1-3-7-56-57-40-53-44-84-62(68(53)80-60(57)17-18-63(56)86)41-59-58(71(84)93)47-105-72(94)74(59,4-2)107-73(95)106-46-51-11-15-54(16-12-51)78-70(92)61(8-5-6-21-75)79-65(88)49-104-48-64(87)76-22-24-96-26-28-98-30-32-100-34-36-102-38-39-103-37-35-101-33-31-99-29-27-97-25-23-83-45-55(81-82-83)42-77-69(91)52-13-9-50(10-14-52)43-85-66(89)19-20-67(85)90;3-1(4)2(5)6/h3,11-12,15-20,40-41,45,50,52,61,86H,1,4-10,13-14,21-39,42-44,46-49,75H2,2H3,(H,76,87)(H,77,91)(H,78,92)(H,79,88);1H,(H,5,6)/t50?,52?,61-,74-;/m0./s1

InChIKey

DVDIERQYFJXMNX-UQWSCRIASA-N

CL2A-Chimmitecan is a novel semi-synthetic compound derived from Camptothecin, a natural alkaloid with potent antineoplastic properties. Structurally, CL2A-Chimmitecan has been optimized to enhance its solubility and stability compared to traditional Camptothecin derivatives. The molecular modifications have also led to improved pharmacokinetic properties, enabling better drug delivery and effectiveness. As a topoisomerase I inhibitor, CL2A-Chimmitecan interferes with DNA replication in cancer cells, inducing cell cycle arrest and apoptosis. This compound has shown promise in preclinical studies for its robust anticancer activity across a variety of cancer models.

One of the key applications of CL2A-Chimmitecan is in the treatment of solid tumors. Due to its enhanced ability to penetrate cellular membranes and target malignant cells while sparing normal tissues, it is being investigated for use against cancers such as colorectal, ovarian, and lung cancer. Clinical trials have been exploring its efficacy as both a monotherapy and in combination with other chemotherapeutic agents, aiming to improve response rates and extend patient survival.

Another significant application is in targeting resistant cancer strains. Cancer cells often develop resistance to conventional therapies, leading to treatment failures. CL2A-Chimmitecan, with its unique mechanism of action, provides a new line of attack against these resistant strains. By effectively overcoming drug efflux mechanisms and altering cellular pathways, it holds potential in managing cancers that are refractory to first-line treatments.

The third application of CL2A-Chimmitecan involves its role in personalized medicine. With advancements in genomic profiling, identifying patients who would benefit most from topoisomerase I inhibitors is becoming feasible. CL2A-Chimmitecan can thus be tailored to individuals based on their genetic makeup, optimizing therapeutic outcomes and minimizing adverse effects. By aligning treatment with genetic insights, it embodies a more targeted and efficient approach to cancer therapy.

Lastly, CL2A-Chimmitecan is being examined for its potential in combination therapies. By synergizing with other molecularly-targeted treatments or immunotherapies, it may amplify anticancer effects and reduce the likelihood of resistance development. This combination approach is particularly appealing in complex cancers where monotherapy may not suffice. The integration of CL2A-Chimmitecan in comprehensive treatment regimens represents a step forward in the ongoing battle against cancer, striving to improve quality of life and survival rates for patients.